{"id":"verteporfin-bevacizumab-triamcinolone-acetonide","safety":{"commonSideEffects":[{"rate":"null","effect":"Visual disturbances"},{"rate":"null","effect":"Increased intraocular pressure"},{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Verteporfin works by accumulating in abnormal blood vessels and releasing energy when exposed to light, causing damage to the vessel walls. Bevacizumab binds to VEGF-A, preventing it from interacting with its receptor and thereby inhibiting the formation of new blood vessels. Triamcinolone acetonide reduces inflammation and swelling by suppressing the production of inflammatory mediators.","oneSentence":"Verteporfin is a photosensitizer that selectively targets and destroys abnormal blood vessels in the eye, while bevacizumab is a monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A), and triamcinolone acetonide is a corticosteroid that reduces inflammation and swelling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:32.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of choroidal neovascularization in age-related macular degeneration"},{"name":"Treatment of macular edema following retinal vein occlusion"},{"name":"Treatment of metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT00376701","phase":"PHASE2","title":"Combination Therapy for Age-Related Macular Degeneration.","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-09","conditions":"Age Related Macular Degeneration","enrollment":103},{"nctId":"NCT00464347","phase":"PHASE2","title":"TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration","status":"TERMINATED","sponsor":"National Eye Institute (NEI)","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT00370539","phase":"PHASE3","title":"Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-09","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"verteporfin, bevacizumab, triamcinolone acetonide","genericName":"verteporfin, bevacizumab, triamcinolone acetonide","companyName":"Shahid Beheshti University of Medical Sciences","companyId":"shahid-beheshti-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Verteporfin is a photosensitizer that selectively targets and destroys abnormal blood vessels in the eye, while bevacizumab is a monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A), and triamcinolone acetonide is a corticosteroid that reduces inflammation and swelling. Used for Treatment of choroidal neovascularization in age-related macular degeneration, Treatment of macular edema following retinal vein occlusion, Treatment of metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}